Biohaven Cash And Short Term Investments from 2010 to 2024
| BHVN Stock | USD 46.38 0.90 1.90% |
Cash And Short Term Investments | First Reported 2017-03-31 | Previous Quarter 436.9 M | Current Value 378.8 M | Quarterly Volatility 150.5 M |
Check Biohaven Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biohaven Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.3 M, Interest Expense of 1.2 M or Selling General Administrative of 60.1 M, as well as many indicators such as Price To Sales Ratio of 0.46, Dividend Yield of 0.0 or PTB Ratio of 7.48. Biohaven financial statements analysis is a perfect complement when working with Biohaven Pharmaceutical Valuation or Volatility modules.
Biohaven | Cash And Short Term Investments |
Latest Biohaven Pharmaceutical's Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Biohaven Pharmaceutical Holding over the last few years. Short Term Investments is an account in the current assets section of Biohaven Pharmaceutical balance sheet. This account contains Biohaven Pharmaceutical investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Biohaven Pharmaceutical Holding fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Biohaven Pharmaceutical's Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biohaven Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Biohaven Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 193,896,045 | |
| Geometric Mean | 167,285,449 | |
| Coefficient Of Variation | 60.44 | |
| Mean Deviation | 97,153,793 | |
| Median | 131,468,000 | |
| Standard Deviation | 117,198,766 | |
| Sample Variance | 13735.6T | |
| Range | 389.3M | |
| R-Value | 0.58 | |
| Mean Square Error | 9769.1T | |
| R-Squared | 0.34 | |
| Significance | 0.02 | |
| Slope | 15,271,242 | |
| Total Sum of Squares | 192297.7T |
Biohaven Cash And Short Term Investments History
About Biohaven Pharmaceutical Financial Statements
Biohaven Pharmaceutical investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how Biohaven Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 381.8 M | 270 M |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Biohaven Stock
Moving against Biohaven Stock
| 0.86 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.69 | RGNX | Regenxbio | PairCorr |
| 0.67 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.65 | INKT | Mink Therapeutics | PairCorr |
| 0.56 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Biohaven Pharmaceutical Correlation against competitors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.